{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-390535","form_type":"8-K","ticker":"KMTS","cik":"0001877184","company_name":"KESTRA MEDICAL TECHNOLOGIES, LTD.","filed_at":"2026-09-14T20:04:29+00:00","discovered_at":"2026-09-14T20:05:00.267979+00:00","generated_at":"2026-09-14T20:05:06.395974+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Kestra Medical raises FY27 revenue guidance to $141M after Q1 revenue up 60% to $31.0M","bullets":["F1Q27 revenue of $31.0M, up 60% YoY; gross margin expanded to 56.5% from 45.7%.","GAAP net loss widened to $44.1M from $25.8M; adjusted EBITDA loss was $24.0M vs $19.4M.","FY27 revenue guidance raised to $141M, representing 48% growth compared to FY26.","Cash and investments totaled $244.7M; total liquidity ~$320M including term-loan availability.","Growth driven by WCD market expansion, competitive share gains, new sales territories, and higher in-network mix."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-390535","json":"https://secwatch.observer/filing/0001193125-26-390535.json","markdown":"https://secwatch.observer/filing/0001193125-26-390535.md","text":"https://secwatch.observer/filing/0001193125-26-390535.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1877184/000119312526390535/0001193125-26-390535-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1877184/000119312526390535/ck0001877184-20260914.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-14T20:05:06.395974+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}